Marijuana and IBD: Challenging Decisions
Though patient use of cannabinoids for the treatment of IBD has increased, clinical decision making on whether to formally recommend it as treatment remains difficult.
Though patient use of cannabinoids for the treatment of IBD has increased, clinical decision making on whether to formally recommend it as treatment remains difficult.
Researchers aimed to better elucidate the role of fDPP-4 levels as a biomarker of IBD activity and to correlate it with certain clinical parameters.
The authors review gut dysfunction and microbiota changes during HIV infection and IBD and discuss how they may induce a dysfunctional mucosal barrier, dysbiosis, and changes on the cellular level, including monocytes, macrophages, and dendritic cells.